Nutr Res Pract.  2007 Jun;1(2):100-104.

Hypoglycemic and hypolipidemic effects of Saururus chinensis Baill in streptozotocin-induced diabetic rats

  • 1Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Institute of Biomedical Engineering, Inje University, Gimhae, Gyungnam 621-749, Korea.
  • 2Amicogen Inc., Sangchon-rhe 694-4, Jinsung-myun, Jinju, Gyungnam 660-852, Korea.


Saururus chinensis Baill was reported to inhibit alpha-glucosidase in vitro and flatten postprandial increase in blood glucose in streptozotocin (STZ)-induced diabetic rats. We studied the effect of chronic consumption of S. chinensis Baill on blood glucose and lipid profile in STZ-induced diabetic male rats fed high fat diet. Male rats weighing 100-120 g were fed 30% fat diet with and without 10% freeze-dried leaves of S. chinensis Baill for 7 weeks after 1 week of adaptation. The rats were rendered diabetic by intravenous injection of STZ (60 mg/kg) after 6-week feeding of the assigned diets. At 1 week after the injection, the rats were sacrificed after an overnight fast. Plasma glucose (380.2 +/- 14.4 mg/dL), total cholesterol (93.9 +/- 7.9 mg/dL) and triglyceride levels (123.6 +/- 7.5 mg/dL) of the S. chinensis Baill group were significantly lower than those of the control group (418.1 +/- 12.0 mg/dL, 119.9 +/- 9.4 mg/dL, 152.0 +/- 10.3 mg/dL, respectively, p<0.05). Chronic consumption of S. chinesis Baill significantly decreased maltase activity of the small intestinal mucosa (120.1 +/- 8.7 U/g protein) compared with the control group (96.8 +/- 7.0 U/g protein, p<0.05). These results suggest that S. chinensis Baill have hypoglycemic and hypolipidemic effects by inhibiting alpha-glucosidase activity in the animal model of diabetes mellitus.


Saururus chinensis Baill; glucose; cholesterol; triglyceride; streptozotocin

MeSH Terms

Blood Glucose
Diabetes Mellitus
Diet, High-Fat
Injections, Intravenous
Intestinal Mucosa
Models, Animal
Blood Glucose


1. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003. 26:S83–S86.
2. A.O.A.C. Official methods of analysis. 1995. 14th ed. Washington DC. USA: Association of official analytical chemists.
3. Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun. 2006. 345:688–693.
4. Balflour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993. 46:1025–1054.
5. Centers for Disease Control and Prevention. Diabetes Surveillance Report. 1999. Atlanta, GA: US Department of Health and Human Services.
6. Chung BS, Shin MG. Dictionary of Korean Folk Medicine. 1990. Seoul. Republic of Korea: Young Lim Sa;813.
7. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 1995. 18:817–824.
8. Dahlqvist A. Assay of intestinal disaccharidases. Scand J Clin Lab Invest. 1984. 44:169–172.
9. Fujita H, Yamagami T. Fermented soybean-derived touchiextract with anti-diabetic effect via alpha-glucosidase inhibitory action in a long-term administration study with KKAy mice. Life Sci. 2001. 70:219–227.
10. Fujita H, Yamagami T, Ohshima K. Fermented soybeanderived touchi extract with anti-glycaemic effect via α-glucosidase inhibitory action in rats and humans. J Nutr. 2001. 131:1211–1213.
11. Fujita H, Yamagami T, Ohshima K. Long-term ingestion of touchi-extract, α-glucosidase inhibitor, by borderline and mild type-2 diabetic subjects is safe and significantly reduces blood glucose levels. Nutr Res. 2003. 23:713–722.
12. Hanefeld M. The Role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1988. 12:228–237.
13. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999. 22:960–964.
14. Joo HJ, Kang MJ, Seo TJ, Kim HA, Yoo SJ, Lee SK, Lim HJ, Byun BH, Kim JI. The hypoglycemic effect of S. chinensis Baill in animal models of diabetes mellitus. Food Science and Biotechnology. 2006. 15:413–417.
15. Juretic D, Bernik S, Cop L, Hadzila M, Petlevski R, Lukac-Bajalo J. Short-term effect of acarbose on specific intestinal disaccharidase activities and hyperglycaemia in CBA diabetic mice. J Anim Physiol Anim Nutr (Berl). 2003. 87:263–268.
16. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998. 21:1414–1431.
17. Kwon CS, Son KH, Kim JS. Effect of Lonicera japonica flower on body weight gain and glucose tolerance in rodents. Food Science and Biotechnology. 2004. 13:768–771.
18. Kwon EH, Jang HS, Kim SW, Choi SW, Rhee SJ, Cho SH. Effects of mulberry juice and cake powders on blood glucose and lipid lowering and erythrocyte antioxidative enzyme activities in sterptozotocin-induced diabetic rats. Korean Journal of Nutrition. 2007. 40:199–210.
19. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews. 1998. 6:132–145.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951. 193:265–275.
21. Matsui T, Yoshimoto C, Osajima K, Oki T, Osajima Y, Oki T, Osajima Y. In vitro survey of α-glucosidase inhibitory food components. Biosci Biotechnol Biochem. 1996. 60:2019–2022.
22. Mughal MA, Memon MY, Zardari MK, Tanwani RK, Ali M. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc. 2000. 50:152–156.
23. Murali B, Upadhyaya UM, Goyal RK. Effect of chronic treatment with Enicostemma littorale in non-insulin-dependent diabetic (NIDDM) rats. J Ethnopharmacol. 2002. 81:199–204.
24. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol. 1995. 30:892–896.
25. Saito N, Sakai H, Sekihara H, Yajima Y. Effect of an α-glucosidase inhibitor (voglibose), in combination with sulphonilureas, on glycaemic control in type 2 diabetes subjects. J Int Med Res. 1998. 26:219–232.
26. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med. 1998. 15:485–491.
27. Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother. 1999. 1:149–156.
28. Stand E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab. 1999. 1:215–220.
29. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in the diabetes control in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.
30. Toeller M. Alpha-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest. 1994. 24:31–35.
31. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ. 1998. 317:703–713.
32. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of α-glucosidase inhibitors from Tochu-cha (Encommia ulmoides). Biosci Biotechnol Biochem. 1997. 61:177–178.
33. Yamashita K, Sugawara S, Sakairi I. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats. Horm Metab Res. 1984. 16:179–182.
34. Yoo SK, Kim MJ, Kim JW, Rhee SJ. Effects of YK-209 mulberry leasves diasaccharidase activities of small intestine and blood glucose-lowering in sterptozotocin-induced diabetic rats. Journal of the Korean Society Food Science and Nutrition. 2002. 31:1071–1077.
35. Zavaroni I, Reaven GM. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor. Metabolism. 1981. 30:417–420.
Full Text Links
  • NRP
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: